It works across orthopaedic trauma, spine, biomaterials, joint reconstruction and enabling technologies, offering education and clinical backing. Nevro’s HFX spinal cord stimulation platform (SCS) ...

Nevro’s comprehensive HFX™ spinal cord stimulation (SCS) platform includes the Senza® SCS system and support services for the treatment of chronic pain of the trunk and limb and painful ...

It has been about a month since the last earnings report for Nevro (NVRO). Shares have added about 0.9% in that time frame, outperforming the S&P 500. Will the recent positive trend continue ...

Nevro develops implantable spinal cord stimulation (SCS) technology. It also offers sacroiliac (SI) joint fusion platforms. The company’s HFX iQ SCS system utilizes AI, high-frequency (10 ...

Nevro's comprehensive HFX™ spinal cord stimulation (SCS) platform includes the Senza ® SCS system and support services for the treatment of chronic pain of the trunk and limb and painful diabetic ...

The deal was first announced in February, and Nevro was valued at $250 million. Nevro employs HFX spinal cord stimulation, which is used in its Senza SCS system. The company also offers minimally ...

StockNews.com began coverage on shares of Nevro (NYSE:NVRO – Free Report) in a report published on Saturday morning. The brokerage issued a hold rating on the medical equipment provider’s stock.